Physician profile
Divya Sivakumar
NPI 1528419587
$19,523.69
in general payments reported to CMS, 2019-2025
41 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,265 · 2020: $183 · 2021: $133 · 2022: $658 · 2023: $1,974 · 2024: $1,111 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $5,013 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,075.00 |
| Food and Beverage | $5,012.97 |
| Education | $196.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,318.52 | 2022-2025 | Ubrelvy, Qulipta, Botox |
| Pfizer INC. | $3,715.70 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $550.18 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Ucb, INC. | $466.93 | 2019-2025 | Rystiggo, Nayzilam |
| Lundbeck LLC | $461.97 | 2023-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $404.66 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Impel Pharmaceuticals INC. | $267.85 | 2022-2023 | Trudhesa |
| Mdd US Operations, LLC | $234.62 | 2019 | |
| Alnylam Pharmaceuticals INC. | $155.88 | 2019 | |
| Neurocrine Biosciences, INC. | $144.19 | 2023-2025 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $130.55 | 2019-2020 | |
| Alkermes, INC. | $125.00 | 2019 | |
| Greenwich Biosciences, INC. | $124.99 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $124.54 | 2022 | |
| Glaxosmithkline, LLC. | $121.82 | 2025 | Arexvy |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divya Sivakumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.